H.R. 1734: Testing, Rapid Analysis, and Narcotic Quality Research Act of 2023
Bill · 118th Congress (2023–2024). Became law, 19 Dec 2023 · Public Law 118-23. Introduced 23 Mar 2023.
Official title: To require coordinated National Institute of Standards and Technology science and research activities regarding illicit drugs containing xylazine, novel synthetic opioids, and other substances of concern, and for other purposes.
Vote results
- House, 4 Dec 2023: agreed to by voice vote; the record lists no member’s position. In the record’s words: “Resolving differences -- House actions: On motion that the House suspend the rules and agree to the Senate amendment Agreed to by voice vote. (text: CR H6087-6088)”
- Senate, 22 Jun 2023: agreed to by unanimous consent; the record lists no member’s position. In the record’s words: “Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.(text of amendment in the nature of a substitute: CR S2250-2251)”
- President: Signed 19 Dec 2023 · Public Law 118-23
How each member voted
White House
Signed (1): Joseph Biden (D, President).
Senate
Agreed to by unanimous consent: the record lists no member’s position.
House
Agreed to by voice vote: the record lists no member’s position.
Summary
Main subject: Directs the National Institute of Standards and Technology to support research and activities on detecting and analyzing xylazine, novel synthetic opioids, and other new psychoactive substances, and directs the Comptroller General to study federal capabilities to respond to such substances. Sec. 2, Sec. 3
Its core areas: National Institute of Standards and Technology measurement research on xylazine, novel synthetic opioids, and other new psychoactive substances; Coordination and voluntary best practices for handling, transporting, and analyzing these substances; Comptroller General study of federal detection and identification capabilities.
Unexpected Items: 0 provisions
What it does
- Sec. 2: Requires the Director of the National Institute of Standards and Technology to support the Institute's intramural basic measurement science and research on analytical methods, measurement technologies, and data tools for substances containing xylazine, novel synthetic opioids, or other new psychoactive substances.
- Sec. 2: Requires the Director to support activities that inform and expand the development of near-real time spectrometry capabilities regarding xylazine, novel synthetic opioids, and other new psychoactive substances.
- Sec. 2: Requires the Director to convene and consult with organizations engaged in analyzing new psychoactive substances, including the Drug Enforcement Administration and the Centers for Disease Control and Prevention, to develop coordinated strategies and voluntary best practices for safe handling, transport, data-sharing, and analysis.
- Sec. 2: Requires the Director to establish or expand partnerships or consortia with other government agencies and persons engaged in related research and development, and to encourage graduate and post-graduate research on detecting xylazine and other new psychoactive substances.
- Sec. 2: Requires the Director to submit a report on implementation to the Senate Committee on Commerce, Science, and Transportation and the House Committee on Science, Space, and Technology not later than 1 year after enactment.
- Sec. 3: Requires the Comptroller General to study federal capabilities to respond to new psychoactive substances such as xylazine, and to report findings to the same two committees not later than 2 years after enactment.
Written automatically from the official text by Claude Sonnet 5.5, an AI model. Written 2 Oct 2026 and published after the automatic checks, without a person reading it first. Every line names the section it came from.
Changed after House passage
Compares the bill as passed by the House, 11 May 2023, with the final text passed by both chambers. About 44% of the wording the House passed stands in the final text.
Removed before the final vote (0)
None.
Added after House passage (1)
- Sec. 3: Study on United States Government technologies and analytical methods to detect and identify new psychoactive substances: Requires the Comptroller General to study Federal Government capabilities to respond to new psychoactive substances such as xylazine, and to report findings to House and Senate committees within 2 years of enactment.